^
    Back
    Association details:
    Biomarker:CD70 expression
    Cancer:Acute Myelogenous Leukemia
    Drug:ALLO-316 (CD70-targeted CAR-T immunotherapy)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    SITC 2022
    Title:

    392 Engineering CD70-directed CAR-NK cells for the treatment of hematological and solid malignancies

    Published date:
    11/08/2022
    Excerpt:
    In functional assays, CD70 knockout CAR-NK cells mediated cytotoxicity against multiple CD70-positive tumor cell lines including AML and RCC both in vitro and in vivo….Overall, the results demonstrate the potential for targeting CD70 with CAR-NK cell therapy for the treatment of AML, RCC, and other CD70-positive malignancies...
    DOI:
    http://dx.doi.org/10.1136/jitc-2022-SITC2022.0392
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2020
    Title:

    1972 Investigation of ALLO-316: A Fratricide-Resistant Allogeneic CAR T Targeting CD70 As a Potential Therapy for the Treatment of AML

    Published date:
    11/04/2020
    Excerpt:
    ALLO-316 cells were highly effective at lysing CD70-expressing target cells and eliminated greater than 99% of cells at the high effector to target (E:T) ratio...Moreover, ALLO-316 cells were able to kill primary AML blasts with CD70 expression ex vivo.
    DOI:
    https://doi.org/10.1182/blood-2020-142161